Table 2.

Antiproliferative effects of the synthesized compounds on gynecological cell lines and NIH-3T3 fibroblasts.^a

compound	conc. (μM)	inhibition of cell proliferation (%) ± SEM [calculated IC50 (μM)]
		MCF7	MDA-MB-231	T47D	NIH-3T3
6a	10	25.7 ± 1.1	–	–	n.d.
	30	70.0 ± 1.0	30.9 ± 2.0	58.9 ± 1.0
6b	10	–	–	38.2 ± 1.5	n.d.
	30	76.8 ± 0.3	72.1 ± 0.4	90.9 ± 0.6
6c	10	–	–	–	n.d.
	30	52.2 ± 2.8	26.8 ± 1.2	83.8 ± 1,3
6d	10	–	–	–	n.d.
	30	35.8 ± 1.1	–	51.4 ± 1.7
6e	10	–	–	–	n.d.
	30	–	–	41.7 ± 2.6
6f	10	–	–	–	n.d.
	30	73.8 ± 0.6	29.3 ± 3.0	72.2 ± 1.7
6g	10	–	–	–	n.d.
	30	47.4 ± 1.5	–	60.7 ± 2.2
6h	10	65.1 ± 0.9	–	74.9 ± 2.4	–
	30	95.1 ± 1.1	90.8 ± 0.5	84.2 ± 1.6	88.3 ± 0.8
		[9.0]		[6.5]	[18.1]
6i	10	–	–	22.2 ± 1.3	n.d.
	30	87.8 ± 0.7	29.2 ± 1.2	78.0 ± 0.6
6j	10	31.0 ± 1.7	–	31.1 ± 2.2	n.d.
	30	86.4 ± 1.4	27.0 ± 1.0	77.5 ± 1.1
7a	10	–	–	57.0 ± 0.9	n.d.
	30	–	–	65.8 ± 1.3
7b	10	–	–	–	n.d.
	30	85.8 ± 1.0	40.6 ± 1.7	89.6 ± 0.7
7c	10	–	–	–	n.d.
	30	23.1 ± 2.6	57.9 ± 2.0	–
7d	10	–	–	31.1 ± 1.7	n.d.
	30	27.9 ± 2.7	–	60.3 ± 1.9
7e	10	–	–	–	n.d.
	30	66.3 ± 1.5	–	95.8 ± 0.2
7f	10	21.1 ± 2.8	31.3 ± 1.3	83.1 ± 1.3	–
	30	95.8 ± 0.3	89.6 ± 0.8	87.5 ± 0.5	84.6 ± 1.3
				[4.3]	[18.2]
7g	10	–	–	22.3 ± 1.3	n.d.
	30	40.9 ± 1.6	39.6 ± 1.7	55.7 ± 2.2
7h	10	–	–	–	n.d.
	30	91.3 ± 0.8	96.8 ± 0.2	85.2 ± 1.1
7i	10	66.8 ± 1.7	31.3 ± 1.5	32.8 ± 1.3	–
	30	96.3 ± 0.2	96.8 ± 0.2	87.8 ± 0.5	94.0 ± 0.5
		[6.9]			[15.3]
7j	10	58.6 ± 1.2	42.0 ± 0.8	48.3 ± 1.9	–
	30	89.5 ± 1.1	96.1 ± 0.2	85.5 ± 1.2	91.1 ± 1.0
		[8.1]			[17.3]
cisplatin	10	66.9 ± 1.8	–	51.0 ± 2.0	94.2 ± 0.4
	30	96.8 ± 0.4	71.5 ± 1.2	55.0 ± 1.5	96.4 ± 0.2
		[5.8]	[19.1]	[9.8]	[3.2]

^aCompounds eliciting less than 20% inhibition of proliferation were considered ineffective and the exact results are not given, for simplicity. n.d.: not determined.